Association of HSP90B1 genetic polymorphisms with efficacy of glucocorticoids and improvement of HRQoL in systemic lupus erythematosus patients from Anhui Province.

Objective: The aim of this study was to investigate the associations between HSP90B1 gene polymorphisms and the efficacy of glucocorticoids (GCs) and the improvement of health-related quality of life (HRQoL) in Anhui patients with systemic lupus erythematosus (SLE). Method: A total of 305 patients with SLE were recruited to the study. These patients were treated with GCs for 12 weeks and classified into two groups (sensitivity and insensitivity) according to the response to GCs measured by the scores on SLE disease activity index (SLEDAI). The HRQoL of SLE patients were evaluated by 36-item Short Form Health Survey (SF-36) at baseline and 12 weeks respectively. HapMap database and Haploview software were used to select HSP90B1 gene tag single nucleotide polymorphisms (SNPs). Benjamini & Hochberg (BH) method based on false discovery rate (FDR) was used for multiple testing correction. Results: A total of 291 patients were included in final data analysis with 14 patients excluded due to loss to follow-up. Among these patients, 160 patients were sensitive to GCs and 131 patients were insensitive to GCs. Twelve tag SNPs of HSP90B1 gene were selected. The rs12426382 polymorphism was associated with the efficacy of GCs (dominant model: crude OR=0.514, 95% CI=0.321-0.824, P=0.006; adjusted OR=0.513, 95% CI=0.317-0.831, P=0.007). After BH correction, there was no association between rs12426382 polymorphism and efficacy of GCs (PBH =0.084). In haplotype analysis, the haplotype CCCGAACATCCC (OR=2.273, 95% CI=1.248-4.139, P=0.006) and CTGGGACGTTC (OR=0.436, 95% CI=0.208-0.916, P=0.025) showed significant associations with the efficacy of GCs. After corrected by BH method, CCCGAACATCCC was still associated with the efficacy of GCs (PBH =0.048). The rs3794241, rs1165681, rs2722188, rs3794240 and rs10861147 polymorphisms were associated with the improvement of HRQoL among SLE patients (P < 0.05). But no association existed after the correction of BH method (P > 0.05). Conclusions: The results of this study demonstrated that HSP90B1 genetic polymorphisms might be associated with the efficacy of GCs, but not associated with the improvement of HRQoL in Anhui population with SLE.

[1]  H. Yamanaka,et al.  Reliability of the SF-36 in Japanese patients with systemic lupus erythematosus and its associations with disease activity and damage: a two-consecutive year prospective study , 2018, Lupus.

[2]  D. Ye,et al.  Single nucleotide polymorphisms of HSP90AA1 gene influence response of SLE patients to glucocorticoids treatment , 2016, SpringerPlus.

[3]  T. Shimoda,et al.  Quality of life in Japanese female patients with systemic lupus erythematosus: Evaluation using the Short Form 36 Health Survey , 2016, Modern rheumatology.

[4]  D. Isenberg,et al.  What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy? , 2015, Expert review of clinical immunology.

[5]  D. Ye,et al.  Glucocorticoid receptor genetic polymorphisms is associated with improvement of health-related quality of life in Chinese population with systemic lupus erythematosus , 2015, Clinical Rheumatology.

[6]  L. Punzi,et al.  Optimizing outcome in SLE: treating-to-target and definition of treatment goals. , 2014, Autoimmunity reviews.

[7]  J. Aviña-Zubieta,et al.  Overall and Cause‐Specific Mortality in Patients With Systemic Lupus Erythematosus: A Meta‐Analysis of Observational Studies , 2014, Arthritis care & research.

[8]  A. Takaki,et al.  Assessment of health‐related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C , 2014, Journal of gastroenterology and hepatology.

[9]  C. Gyawali,et al.  Genetic variation in the beta‐2 adrenergic receptor (ADRB2) predicts functional gastrointestinal diagnoses and poorer health‐related quality of life , 2013, Alimentary pharmacology & therapeutics.

[10]  D. Cabanes,et al.  Listeria monocytogenes Triggers the Cell Surface Expression of Gp96 Protein and Interacts with Its N Terminus to Support Cellular Infection* , 2012, The Journal of Biological Chemistry.

[11]  D. Hwang,et al.  A novel pathogenic role of the ER chaperone GRP78/BiP in rheumatoid arthritis , 2012, The Journal of experimental medicine.

[12]  Y. Argon,et al.  GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum. , 2012, Biochimica et biophysica acta.

[13]  K. Nagata,et al.  ER Stress Proteins in Autoimmune and Inflammatory Diseases , 2012, Front. Immun..

[14]  R. Binder,et al.  CD91-dependent programming of T-helper cell responses following heat shock protein immunization. , 2011, Nature communications.

[15]  Shigeaki Suzuki,et al.  Autoimmunity to endoplasmic reticulum chaperone GRP94 in myasthenia gravis , 2011, Journal of Neuroimmunology.

[16]  Sunghoon Kim,et al.  Identification of gp96 as a Novel Target for Treatment of Autoimmune Disease in Mice , 2010, PloS one.

[17]  Y. Shoenfeld,et al.  The geoepidemiology of systemic lupus erythematosus. , 2010, Autoimmunity reviews.

[18]  Ying Wang,et al.  Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus , 2009, Nature Genetics.

[19]  P. Tak,et al.  Heat Shock Protein 96 Is Elevated in Rheumatoid Arthritis and Activates Macrophages Primarily via TLR2 Signaling 1 , 2009, The Journal of Immunology.

[20]  V. Strand,et al.  Health-related quality of life in patients with systemic lupus erythematosus: an update. , 2007, Annals of the Academy of Medicine, Singapore.

[21]  R. Kaufman,et al.  The unfolded protein response , 2006, Neurology.

[22]  Zihai Li,et al.  Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Y. Nasuhara,et al.  Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. , 1996, British journal of pharmacology.

[24]  J E Ware,et al.  Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. , 1998, Journal of clinical epidemiology.

[25]  R. Morimoto,et al.  Stress–inducible responses and heat shock proteins: New pharmacologic targets for cytoprotection , 1998, Nature Biotechnology.

[26]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[27]  W. Pratt,et al.  The Cyclosporin A-binding Immunophilin CyP-40 and the FK506-binding Immunophilin hsp56 Bind to a Common Site on hsp90 and Exist in Independent Cytosolic Heterocomplexes with the Untransformed Glucocorticoid Receptor (*) , 1995, The Journal of Biological Chemistry.

[28]  C. Malchoff,et al.  Glucocorticoid Resistance , 2020, Definitions.

[29]  H. Söling,et al.  Systemic lupus erythematosus is associated with increased auto‐antibody titers against calreticulin and Grp94, but calreticulin is not the Ro/SS‐A antigen , 1994, European journal of clinical investigation.

[30]  S. Detera-Wadleigh,et al.  The genomic structure of the human glucocorticoid receptor. , 1991, The Journal of biological chemistry.